Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Encorafenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 22,998Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Braftovi

    02 1Braftovi/Mektovi

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 48

    2018 Revenue in Millions : 0

    Growth (%) : New launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 160

    2019 Revenue in Millions : 48

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 187

    2020 Revenue in Millions : 160

    Growth (%) : 17

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Ono Pharma

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 18

    2020 Revenue in Millions : 0

    Growth (%) : 100

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Ono Pharmaceuticals

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 25

    2021 Revenue in Millions : 18

    Growth (%) : 39

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 194

    2021 Revenue in Millions : 187

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 213

    2022 Revenue in Millions : 194

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Braftovi

    Encorafenib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi

    Japan
    arrow
    APGA Annual Conference
    Not Confirmed

    Ono Pharmaceuticals

    Encorafenib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 23

    2022 Revenue in Millions : 25

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Braftovi/Mektovi

    Encorafenib/Binimetinib

    arrow
    APGA Annual Conference
    Not Confirmed

    Brand Name : Braftovi/Mektovi

    U.S.A
    arrow
    APGA Annual Conference
    Not Confirmed

    Pfizer Inc.

    Encorafenib/Binimetinib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 607

    2023 Revenue in Millions : 477

    Growth (%) : 27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF